ARMADA-
Free Consultation
510-200-8695CALL OR TEXT
ARMADAIn the days of the Armada, a fleet of warships, the scuttlebutt was the rumor or gossip that would spread throughout the ship. Today, Armada Law Corp presents The Scuttlebutt, a daily summery of news articles that people within the cannabis, hemp and plant medicine industries are chatting about along with links to the full articles.
In today’s news:
#californiacannabis – “Shortly before 10:00 yesterday morning, Mendocino County Supervisor Glenn McGourty reported from an unusual closed session before the regular Board of Supervisors meeting that, “The Board voted unanimously to accept the resignation of Director Nevedal.”
Cannabis Department Director Kristin Nevedal was hired two years ago this month as the cannabis program manager. She was recruited by Supervisor Ted Williams, who had high hopes for her ability to get applicants through a program fraught with frustrations since its inception. Prior to Nevedal, three ag commissioners, three cannabis program managers, and a Planning and Building Director also tried and failed to administer the cannabis ordinance. Applications have dragged on for years as state and county rules shift. Cultivators have run out of time, money, and hope. Only a bare minority have gotten their state licenses.”
#psychedelics – “Overall, the global regulatory landscape for psychedelic drugs is complex and evolving, with increasing recognition of their potential therapeutic benefits and growing calls for their reclassification and increased access for medical and research purposes. However, significant legal and regulatory barriers remain, particularly in countries where these drugs are classified as Schedule I substances with no accepted medical use.”
#psychedelics – “However, the stigmatization and illegality of psychedelics in the 1960s has left some individuals who could benefit from psilocybin without access to an effective treatment. After the explosion of psychedelic drug use in the 1960s, then-President Richard Nixon approved the Controlled Substances Act, which made the use of such drugs illegal. At this time, and for decades after, until the early 2000s, research on psychedelics was effectively halted. By 2017, at around the same time as researchers developed new brain stimulation technology to treat individuals with certain mental disorders, psychedelic research reemerged on a grand scale. With the arrival of new biotechnology and a renewed focus on psychedelics, 2017 was a turning point in the development of trauma treatments. Since then, psychedelic research has made its way into the mainstream conversation by virtue of its ubiquity. Of 105 registered clinical trials surrounding psychedelics conducted from 2007 to 2020, 77.1% of studies commenced in 2017 or later.”
https://www.psychologytoday.com/us/blog/from-obscurity/202303/the-stigma-of-psychedelics
#CBD – “A Republican congressman told the head of the Food and Drug Administration (FDA) on Wednesday that the agency’s failure to enact regulations for CBD is one of several problems that is “disrupting public confidence” in its abilities.
Rep. Andy Harris (R-MD) said during a House Appropriations subcommittee hearing that “controversies swirl around the agency.” One of those controversies is the fact that FDA hasn’t identified a “regulatory pathway for cannabidiol oil after five years and millions of dollars of investments.””
#cannabisindustry – “Kentucky lawmakers on Thursday gave final approval to a bipartisan bill to legalize medical marijuana, sending the legislation to the governor’s desk.
The House of Representatives approved the legislation — S.B. 47 — on a 66-33 floor vote Thursday. The state Senate had approved the legislation on a 26-11 vote two weeks prior.
The bill would establish a medical cannabis program under the ambit of the state’s Cabinet for Health and Family Service. The bill would not establish any new taxes.”
